A pilot characterization of human lung NSCLC by protein pathway activation mapping

Journal of Thoracic Oncology

Volumn 7, Issue 12, 2012, Pages 1755-1766

  Zupa, Angela ^a   Improta, Giuseppina ^a   Silvestri, Alessandra ^b   Pin, Elisa ^b   Deng, Jianghong ^c   Aieta, Michele ^a   Musto, Pellegrino ^a   Nitti, Donato ^d   Mammano, Enzo ^d   Liotta, Lance ^b   Belluco, Claudio ^b   Wulfkuhle, Julia ^c   Petricoin, Emanuel ^c  

^a REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c GEORGE MASON UNIVERSITY   (United States)

^d UNIVERSITY OF PADOVA   (Italy)

Author keywords

Cell signaling; Non small cell lung cancer; Protein pathway activation mapping; Reverse phase protein microarrays

Indexed keywords

ACTIVATED CDC42 ASSOCIATED KINASE; AUTOPHAGY PROTEIN 5; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; FOCAL ADHESION KINASE 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; JANUS KINASE; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE; PROTEIN KINASE B; PROTEIN RET; SMAD PROTEIN; SOMATOMEDIN RECEPTOR; STAT PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN TISSUE; LASER CAPTURE MICRODISSECTION; LUNG NON SMALL CELL CANCER; LYMPH NODE; MALE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEIN PATHWAY ACTIVATION MAPPING; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 84870332849     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182725fc7     Document Type: Article

References (63)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533-543. (Pubitemid 33586866)
2. Boyle P and Ferlay J. Cancer incidence and mortality in Europe 2004. Ann.Oncol. 2005;6:481-488. (Pubitemid 40458328)
3. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30. (Pubitemid 40310185)
4. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J 2001;18:1059-1068. (Pubitemid 34092881)
5. Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer 1995;75(1 Suppl):191-202.
6. Franceschi S, Bidoli E. The epidemiology of lung cancer. Ann Oncol 1999;10 Suppl 5:S3-S6. (Pubitemid 29522774)
7. Goldstraw P, Crowley J, Chansky K, et al.; International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2:706-714. (Pubitemid 47357522)
8. Kurie JM, Shin HJ, Lee JS, et al. Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clin Cancer Res 1996;2:1787-1793. (Pubitemid 26356366)
9. Hayes DN, Monti S, Parmigiani G, et al. Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J Clin Oncol 2006;24:5079-5090. (Pubitemid 46631412)
10. Weir BA, Woo MS, Getz G, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007;450:893-898. (Pubitemid 350231325)
11. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008;455:1069-1075.
12. Bryant CM, Albertus DL, Kim S, et al. Clinically relevant characterization of lung adenocarcinoma subtypes based on cellular pathways: an international validation study. PLoS ONE 2010;5:e11712.
13. Machida K, Eschrich S, Li J, et al. Characterizing tyrosine phosphorylation signaling in lung cancer using SH2 profiling. PLoS ONE 2010;5:e13470.
14. Yu G, Xiao CL, Lu CH, et al. Phosphoproteome profile of human lung cancer cell line A549. Mol Biosyst 2011;7:472-479.
15. Wang YT, Tsai CF, Hong TC, et al. An informatics-assisted label-free quantitation strategy that depicts phosphoproteomic profiles in lung cancer cell invasion. J Proteome Res 2010;9:5582-5597.
16. VanMeter AJ, Rodriguez AS, Bowman ED, et al. Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type. Mol Cell Proteomics 2008;7:1902-1924.
17. Nanjundan M, Byers LA, Carey MS, et al. Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence. J Thorac Oncol 2010;5:1894-1904.
18. Anderson L, Seilhamer J. A comparison of selected mRNA and protein abundances in human liver. Electrophoresis 1997;18:533-537. (Pubitemid 27174443)
19. Gygi SP, Rochon Y, Franza BR, Aebersold R. Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 1999;19:1720-1730. (Pubitemid 29098230)
20. Shankavaram UT, Reinhold WC, Nishizuka S, et al. Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther 2007;6:820-832. (Pubitemid 46554552)
21. Piyathilake CJ, Frost AR, Manne U, et al. Differential expression of growth factors in squamous cell carcinoma and precancerous lesions of the lung. Clin Cancer Res 2002;8:734-744. (Pubitemid 34742102)
22. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
23. Scagliotti GV, Selvaggi G, Novello S, Hirsch FR. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res 2004;10(12 Pt 2):4227s-4232s. (Pubitemid 38812451)
24. Ohsaki Y, Tanno S, Fujita Y, et al. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep 2000;7:603-607.
25. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37 Suppl 4:S9-15.
26. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-137. (Pubitemid 33674041)
27. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19:6550-6565. (Pubitemid 32197693)
28. Engelman JA, Cantley LC. The role of the ErbB family members in non-small cell lung cancers sensitive to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res 2006;12(14 Pt 2):4372s-4376s. (Pubitemid 44197184)
29. Rosell R, Viteri S, Molina MA, Benlloch S, Taron M. Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer. Curr Opin Oncol 2010;22:112-120.
30. Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 2001;8:3-9. (Pubitemid 32520250)
31. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 2003;8:303-306. (Pubitemid 36929716)
32. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500. (Pubitemid 38720929)
33. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139. (Pubitemid 38637993)
34. Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005;23:2513-2520. (Pubitemid 47050841)
35. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-13311. (Pubitemid 39209661)
36. Yun CH, Boggon TJ, Li Y, et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 2007;11:217-227. (Pubitemid 46349842)
37. Carey KD, Garton AJ, Romero MS, et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res 2006;66:8163-8171. (Pubitemid 44299184)
38. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
39. Riely GJ, Pao W, Pham D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006;12(3 Pt 1):839-844. (Pubitemid 43259866)
40. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-1043. (Pubitemid 46799492)
41. Linardou H, Dahabreh IJ, Kanaloupiti D, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008;9:962-972.
42. Dahabreh IJ, Linardou H, Siannis F, Kosmidis P, Bafaloukos D, Murray S. Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2010;16:291-303.
43. Zhang G, Fang B, Liu RZ, et al. Mass spectrometry mapping of epidermal growth factor receptor phosphorylation related to oncogenic mutations and tyrosine kinase inhibitor sensitivity. J Proteome Res 2011;10:305-319.
44. Emmert-Buck MR, Bonner RF, Smith PD, et al. Laser capture microdissection. Science 1996;274:998-1001. (Pubitemid 26398425)
45. Espina V, Wulfkuhle JD, Calvert VS, et al. Laser-capture microdissection. Nat Protoc 2006;1:586-603.
46. Paweletz CP, Charboneau L, Bichsel VE, et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 2001;20:1981-1989. (Pubitemid 32458030)
47. Wulfkuhle JD, Speer R, Pierobon M, et al. Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J Proteome Res 2008;7:1508-1517.
48. Pierobon M, Calvert V, Belluco C, et al. Multiplexed cell signaling analysis of metastatic and nonmetastatic colorectal cancer reveals COX2-EGFR signaling activation as a potential prognostic pathway biomarker. Clin Colorectal Cancer 2009;8:110-117.
49. Silvestri A, Colombatti A, Calvert VS, et al. Protein pathway biomarker analysis of human cancer reveals requirement for upfront cellular-enrichment processing. Lab Invest 2010;90:787-796.
50. McMillen E, Ye F, Li G, Wu Y, Yin G, Liu W. Epidermal growth factor receptor (EGFR) mutation and p-EGFR expression in resected non-small cell lung cancer. Exp Lung Res 2010;36:531-537.
51. Havaleshko DM, Smith SC, Cho H, et al. Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer. Neoplasia 2009;11:1185-1193.
52. Patnaik SK, Kannisto E, Knudsen S, Yendamuri S. Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection. Cancer Res 2010;70:36-45.
53. Kadara H, Behrens C, Yuan P, et al. A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis. Clin Cancer Res 2011;17:1490-1501.
54. Gordon GJ, Richards WG, Sugarbaker DJ, Jaklitsch MT, Bueno R. A prognostic test for adenocarcinoma of the lung from gene expression profiling data. Cancer Epidemiol Biomarkers Prev 2003;12:905-910. (Pubitemid 37151527)
55. Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002;8:816-824.
56. Larsen JE, Pavey SJ, Passmore LH, Bowman RV, Hayward NK, Fong KM. Gene expression signature predicts recurrence in lung adenocarcinoma. Clin Cancer Res 2007;13:2946-2954. (Pubitemid 46849569)
57. Dhillon T, Mauri FA, Bellezza G, et al. Overexpression of the mammalian target of rapamycin: a novel biomarker for poor survival in resected early stage non-small cell lung cancer. J Thorac Oncol 2010;5:314-319.
58. Yang DK, Son CH, Lee SK, Choi PJ, Lee KE, Roh MS. Forkhead box M1 expression in pulmonary squamous cell carcinoma: correlation with clinicopathologic features and its prognostic significance. Hum Pathol 2009;40:464-470.
59. Tang JM, He QY, Guo RX, Chang XJ. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 2006;51:181-191.
60. Yoshizawa A, Fukuoka J, Shimizu S, et al. Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer. Clin Cancer Res 2010;16:240-248.
61. Jeon HS, Jen J. TGF-beta signaling and the role of inhibitory Smads in non-small cell lung cancer. J Thorac Oncol 2010;5:417-419.
62. Janku F, Stewart DJ, Kurzrock R. Targeted therapy in non-small-cell lung cancer-is it becoming a reality? Nat Rev Clin Oncol 2010;7:401-414.
63. Maione P, Gridelli C, Troiani T, Ciardiello F. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC. Oncologist 2006;11:274-284.